Prof Alison Birtle (Lancashire Teaching Hospitals NHS Foundation Trust, Preston, UK), Dr Pasquale Rescigno (Newcastle University, Newcastle, UK), Prof Gunhild von Amsberg (Martini Clinic, Hamburg, Germany) and Dr Alejo Rodríguez-Vida (Hospital del Mar, Barcelona, Spain) optimising the personalisation of prostate cancer treatment.

They discuss the value of testing for patient outcomes and explore PSA response in mHSPC in the real world.

They also talk about efficacy and QoL in mHSPC, and the significance of BRCA1/2 mutations in mCRPC outcomes.

The panel covers trials like PEACE-1, PEACE-3, STAMPEDE, ENZAMET, and MAGNITUDE.